Table of Contents
Researchers have uncovered a previously unknown mechanism that helps aging cells drive the chronic inflammation linked to many age-related diseases, identifying a mitochondrial epigenetic SASP pathway that opens the door to a new therapeutic approach for promoting healthier aging.
What the Mitochondrial Epigenetic SASP Pathway Reveals
The findings reveal how dysfunctional mitochondria, the cell’s energy-producing structures, work with the cell’s epigenetic machinery to switch on inflammatory genes. The study, published in Nature, builds upon years of research showing that senescent, or “zombie,” cells accumulate with age. While these cells no longer divide, they remain metabolically active and release a cocktail of inflammatory molecules known as the senescence-associated secretory phenotype, or SASP.
Why This Persistent Inflammation Matters
This persistent inflammation is thought to contribute to frailty, cardiovascular disease, cancer, neurodegeneration and other disorders of aging, making the underlying mechanism driving it a significant target for research into age-related disease prevention.
A Different Strategy Behind This Mitochondrial Epigenetic SASP Pathway Research
“For years, the field has focused on getting rid of senescent cells,” says João Passos, PhD, a Mayo Clinic researcher and senior author of the study conducted in collaboration with Sanford Burnham Prebys Medical Discovery Institute. “Our strategy has been different. Instead of killing the cells, we asked whether we could switch off the inflammation that makes them harmful.”
Building on Prior Passos Lab Research
Previous work from the Passos laboratory demonstrated that damaged mitochondria leak mitochondrial DNA and RNA into the cell, activating immune pathways that trigger inflammation. The new study identifies a second, independent pathway that is equally essential to fully activating that inflammatory response.
How Acetyl-CoA Drives This Mitochondrial Epigenetic SASP Pathway
“We found that inflammatory signaling alone isn’t enough. The cells also need a metabolic signal from mitochondria that changes how inflammatory genes are turned on,” says Helene Martini, PharmD, PhD, a Mayo Clinic researcher and first author of the study. The researchers discovered that senescent cells increase production of acetyl-CoA, a molecule generated through mitochondrial metabolism. Acetyl-CoA enables epigenetic modifications, chemical changes that regulate whether genes are switched on or off without altering the DNA sequence itself, that make inflammatory genes more accessible, allowing them to be robustly expressed.
A Two-Signal Model for Inflammation
In other words, mitochondrial DNA and RNA provide the inflammatory alarm, while mitochondrial metabolism grants the molecular “permission” needed to fully activate inflammatory genes. “This is a completely new pathway,” says Dr. Martini. “We found that dysfunctional mitochondria can promote inflammation by controlling epigenetic switches that turn inflammatory genes on.”
A Promising Therapeutic Target Within This Mitochondrial Epigenetic SASP Pathway
The team also identified a promising therapeutic target: a mitochondrial citrate transporter known as SLC25A1. Blocking this transporter reduced the supply of acetyl-CoA, limiting activation of inflammatory genes even though the initial immune signals remained present.
What This Control Point Could Mean for Treatment
Together, these findings reveal a previously unrecognized control point that could be exploited to promote healthier aging, offering researchers a specific molecular target, rather than the broader and more difficult approach of eliminating senescent cells entirely, for reducing the harmful inflammation these cells produce.
How This Fits Mayo Clinic’s Broader Precure Research Initiative
The research is part of a larger effort at Mayo Clinic called the Precure Research initiative, which is focused on developing tools that empower clinicians to predict and intercept biological processes before they evolve into disease or progress into complex, hard-to-treat conditions.
Why This Framing Matters for Future Applications
Positioning this discovery within the broader Precure initiative suggests Mayo Clinic views the mitochondrial epigenetic SASP pathway not merely as a basic science finding, but as a potential building block for future clinical tools aimed at intercepting age-related inflammatory disease processes before they fully manifest.
What This Mitochondrial Epigenetic SASP Pathway Research Means Going Forward
By identifying SLC25A1 as a specific, druggable target within this newly discovered pathway, researchers now have a concrete molecular starting point for developing interventions aimed at reducing senescence-driven inflammation without needing to eliminate senescent cells themselves. Given that this approach targets the mechanism controlling inflammatory gene activation rather than the cells producing the inflammation, it may offer a complementary strategy to existing senolytic approaches that focus on clearing senescent cells directly.
What to Watch Going Forward
As researchers continue investigating this newly identified pathway, the field will likely watch for follow-up studies testing whether pharmacological inhibition of SLC25A1 can safely and effectively reduce inflammatory outcomes in animal models before any translation toward human therapeutics. Given Mayo Clinic’s broader Precure Research initiative focus on intercepting disease processes early, this mitochondrial epigenetic SASP pathway discovery may inform future diagnostic or therapeutic tools aimed at identifying and addressing harmful inflammation in aging patients before it progresses into frailty, cardiovascular disease, or other age-related conditions.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed.
